Phase 1Data readout

Obecabtagene Autoleucel (Obe-Cel)

Multiple Sclerosis (MS)

AUTLAutolus Therapeutics

Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset: Obecabtagene Autoleucel (Obe-Cel)
Development stage: Phase 1
Event type: Data readout
Indication: Multiple Sclerosis (MS)

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for Obecabtagene Autoleucel (Obe-Cel) in Multiple Sclerosis (MS). The expected timing is based on the latest available company guidance and may change.

Development notes

08/11/26:- BOBCAT initial data now expected Q1 2027; larger dataset expected H2 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Obecabtagene Autoleucel (Obe-Cel)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T)

AUCATZYL/Obecabtagene Autoleucel (AUTO1) (CD19 CAR-T)

obe-cel (AUTO1) (CD19)

AUTO8 (BCMA & CD19) (BCMA CD19 CAR-T)